Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Mesothelioma 3Solid Tumor 2Mesothelioma, Malignant 2Uveal Melanoma 1Solid Tumor, Adult 1Recurrence 1MMR-D/MSI-H Colorectal Cancers 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1Advanced Solid Tumor, Adult 1Advanced Solid Tumor 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mesothelioma × niraparib × Other solid neoplasm × Clear all
NCT05455424 2025-05-15

NERO

University Hospital Southampton NHS Foundation Trust

Phase 2 Completed
88 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Recurrence

NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

University of Florida

Phase 2 Completed
37 enrolled 15 charts
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

NCT04940637 2023-05-12

UNITO-001

University of Turin, Italy

Phase 2 Unknown
70 enrolled
Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡